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Essentials
• Platelet transfusion suffers from availability, portability, contamination, and short shelf-life.
• SynthoPlate TM (synthetic platelet technology) can resolve platelet transfusion limitations.
• SynthoPlate TM does not activate resting platelets or stimulate coagulation systemically.
• SynthoPlate TM significantly improves hemostasis in thrombocytopenic mice dose-dependently.
Summary. Background: Platelet transfusion applications face severe challenges, owing to the limited availability and portability, high risk of contamination and short shelf-life of platelets. Therefore, there is significant interest in synthetic platelet substitutes that can provide hemostasis while avoiding these issues. Platelets promote hemostasis by injury site-selective adhesion and aggregation, and propagation of coagulation reactions on their membranes. On the basis of these mechanisms, we have developed a synthetic platelet technology (SynthoPlate TM ) that integrates platelet-mimetic site-selective 'adhesion' and 'aggregation' functionalities via heteromultivalent surface decoration of lipid vesicles with von Willebrand factor-binding, collagen-binding and active platelet integrin glycoprotein (GP) IIb-IIIa-binding peptides. Objective: To evaluate SynthoPlate for its effects on platelets and plasma in vitro, and for systemic safety and hemostatic efficacy in severely thrombocytopenic mice in vivo. Methods: In vitro, SynthoPlate was evaluated with aggregometry, fluorescence microscopy, microfluidics, and thrombin and fibrin generation assays. In vivo, SynthoPlate was evaluated for systemic safety with prothrombin and fibrin assays on plasma, and for hemostatic effects on tail-transection bleeding time in severely thrombocytopenic (TCP) mice. Results: SynthoPlate did not aggregate resting platelets or spontaneously promote coagulation in plasma, but could amplify the recruitment and aggregation of active platelets at the bleeding site, and thereby site-selectively enhance fibrin generation.
Introduction
Platelet transfusion is clinically important in the management of bleeding complications [1] [2] [3] [4] . However, donorderived platelets present issues of limited availability and portability, the need for antigen matching, a high risk of bacterial contamination, and a short shelf-life [5] [6] [7] [8] [9] . Although robust research is being directed at resolving these issues, there is significant clinical interest in 'donorindependent' platelet technologies [10] [11] [12] [13] . A promising research area in this respect is 'synthetic platelet substitutes' [14] . To this end, we report on a 'synthetic platelet' technology (SynthoPlate TM ), whose design is based on mimicking platelets' primary hemostasis mechanisms of injury site-specific adhesion (to collagen and von Willebrand factor [VWF] ) and aggregation (via fibrinogen [Fg] -mediated bridging of integrin glycoprotein [GP] IIbIIIa on activated platelets) [15] [16] [17] . Integration of these platelet-mimetic dual functionalities was achieved via heteromultivalent surface decoration of biocompatible lipid vesicles with VWF-binding peptide (VBP), collagenbinding peptide (CBP), and active GPIIb-IIIa-binding Fg-mimetic peptide (FMP) (Fig. 1) [18] . We have previously demonstrated that this integrative design results in superior hemostatic performance than 'adhesion-only' and 'aggregation-only' designs [19, 20] . Also, in platelets' hemostatic action, colocalization of coagulation factors on the surfaces of activated procoagulant platelets at the bleeding site results in amplification of thrombin and fibrin generation (secondary hemostasis) [21] . Thus, we hypothesized that SynthoPlate-mediated direct enhancement of platelet recruitment and aggregation at an injury site would, in effect, also enhance secondary hemostatic output at that site (the envisioned mechanism is shown in Fig. S1 ). Therefore, we focused here on characterizing the capabilities of SynthoPlate vesicles regarding primary and secondary hemostatic mechanisms in vitro, and subsequently evaluated the systemic safety and hemostatic efficacy of SynthoPlate in vivo in a mouse model of thrombocytopenia [22] . (FMP) were custom-synthesized by Genscript (Piscataway, NJ, USA), conjugated to DSPE-PEG 2000 -COOH, and characterized by mass spectrometry (Fig. S2) . Phosphatebuffered saline (PBS), bovine serum albumin (BSA), sodium bicarbonate and fluorescent human Fg (Alexa Fluor-647-labeled) were from Thermo Fisher (Waltham, MA, USA). Cholesterol and rat tail type I collagen were from Sigma-Aldrich (Saint Louis, MO, USA), ADP was from Bio/Data Corporation (Horsham, PA, USA) and human VWF (FXIII-free) was from Hematologic Technologies (Essex Junction, VT, USA). Citrated human whole blood was obtained from freshly donated stock from healthy donors at Case School of Medicine. The parallel-plate flow chamber (PPFC) system was from Glycotech (Gaithersburg, MD, USA). For mouse studies, MOPC-21, anti-CD41 and anti-CD42 antibodies were from Abcam (Cambridge, MA, USA). For immunostaining, rat antimouse CD41 antibodies were from Bio-Rad (Hercules, CA, USA), fluorescein isothiocyanate (FITC)-labeled donkey-anti-rat IgG was from Thermo Fisher, rat anti-mouse CD31 was from Biolegend (San Diego, CA, USA) and goat anti-rat Alexa Fluor-633-IgG was from Thermo Fisher. For immunoblot studies, lysis buffer (RIPA) was from Sigma-Aldrich, protease inhibitors were from Roche Applied Science (Madison, WI, USA), phosphatase inhibitors and aprotinin were from Sigma-Aldrich, corn trypsin inhibitor was from Hematologic Technologies, the Protein DC assay was from Bio-Rad, rabbit polyclonal Fg/fibrin antibody was from Life Span Biosciences (Seattle, WA, USA), horseradish peroxidase (HRP)-conjugated secondary antibody was from Cell Signaling (Danvers, MA, USA), super signal west Pico chemiluminiscent substrate was from Thermo Fisher, and antibodies against b-actin were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). All in vivo studies were carried out as per approved Institutional Animal Care and Use Committee protocols at Cleveland Clinic and the University of Pittsburgh.
Materials and methods

Manufacture of SynthoPlate
The SynthoPlate design utilizes a clinically relevant poly (ethylene glycol)-modified lipid vesicle platform, refined by heteromultivalent ligand decoration [23] . For this, DSPC, cholesterol, DSPE-PEG-VBP, DSPE-PEG-CBP and DSPE-PEG-FMP were homogenously mixed at mole fractions of 0.50, 0.45, 0.0125, 0.0125 and 0.025, respectively, in 1 : 1 methanol/chloroform, and this lipid mixture was subjected to reverse-phase evaporation, PBS-based hydration, and subsequent extrusion through a 200-nm-pore membrane (Northern Lipids, Burnaby, BC, Canada) to yield heteromultivalently surface-decorated SynthoPlate vesicles (a schematic is shown in Fig. 1A ). Dynamic light scattering, scanning electron microscopy and cryo-transmission electron microscopy characterization indicated vesicles 150 nm in diameter (Fig. 1B-D) . On the basis of these parameters, the theoretical ligand density per vesicle is~5 0 000 (Data S1). By use of a Malvern zetasizer, the zeta potential of SynthoPlate was found to be À 24.9 AE 8.00 mV, and that for control (unmodified) particles was found to be À 25.2 AE 9.77 mV.
In vitro studies of the SynthoPlate effect on platelet aggregation
Turbidimetric experiments were carried out on plateletrich plasma (PRP) with ADP as agonist, or on washed platelets (Plts) with collagen as agonist, by use of a Chrono-log Aggregometer (Chrono-log, Havertown, PA, USA), to test the interaction of SynthoPlate with active versus resting platelets. Wild-type C57Bl-6 mice were anesthetized, and whole blood was drawn by venipuncture with 0.109 M sodium citrate. Modified Tyrode's buffer (0.7 v/v) was added, and PRP was separated by centrifugation (150 9 g, 20 min). The platelet concentration in PRP was adjusted to 2.50 9 10 8 mL -1 with platelet-poor plasma (PPP). To prepare washed platelets, PRP was further centrifuged at 650 9 g for 6 min in the presence of 0.5 lM prostaglandin E 1 (PGE1). The resultant platelet pellet was resuspended in PBS containing 0.109 M sodium citrate (9 : 1, v/v) and 0.5 lM PGE1, repelleted, and resuspended in PBS to a concentration of 2.50 9 10 8 mL -1 . Aggregometry studies were conducted at 37°C with stirring at 1200 r.p.m. ADP-mediated aggregation was performed with 400 lL of PRP (labeled as 100% PRP in Fig. 2A ), or PRP diluted 50% (v/v) with either PPP (50% PRP in Fig. 2A ) or PPP containing SynthoPlate or PPP containing control particles with a particle concentration of 5.00 9 10 10 mL -1
. To further ensure that the effect of SynthoPlate (or control particles) was specifically on platelets, collagen-based aggregation studies were performed with washed platelets instead of PRP (labeled as 100% Plts or 50% Plts in Fig. 2B ), and here particles were suspended in PBS instead of PPP. Aggregation was monitored with the addition of a final concentration of 1 mM Ca 2+ /Mg 2+ and with or without the addition of platelet agonists (ADP at 2.5 lM and collagen at 1 lg mL
À1
). The 50% dilution of platelets was considered to be a thrombocytopenic (TCP) condition, as rationalized from the clinical definition [24] . The same SynthoPlate and control particles were also used to characterize the particle-mediated recruitment and aggregation of active platelets on 'VWF + collagen'-coated surfaces under flow in the PPFC, imaged under fluorescence microscopy. For this, calcein-stained (green fluorescent) platelets suspended in plasma (50 000 mL À1 ) were passed over 'VWF + collagen'-coated surfaces along with RhBlabeled (red fluorescence) SynthoPlate (or control) particles, ADP (2.5 lM), and soluble VWF (10 lg mL À1 ), with an adaptation of previously published methodology [25, 26] . The flow was maintained at shear stress of 50 dyn cm À2 (shear rate of > 3000 s
, assuming plasma to be a Newtonian fluid with a constant viscosity of 0.015 P) to ensure a hemostatically relevant interaction of VWF with collagen [27] . The colocalization of active platelets (green) and particles (red) on the surfaces was imaged with a Zeiss inverted fluorescence microscope (Thornwood, NY, USA) (schematic [A] in Fig. S3 ).
In vitro studies of SynthoPlate effects on thrombin and fibrin generation
Experiments were carried out to first study whether SynthoPlate vesicles themselves spontaneously generate thrombin in human plasma (i.e. assessing systemic coagulation risk). PRP was obtained from freshly drawn citrated human whole blood by centrifugation (150 9 g, 15 min), and PPP was obtained by further centrifugation of PRP (2500 9 g, 20 min). The thrombin-cleavable fluorogenic substrate (p-tosyl-Gly-Pro-Arg) 2 -Rhodamine-110 (Thermo Fisher) at a final concentration of 0.1 mM (in Tris buffer, pH 7.4, 22°C) was incubated in the presence of 5% v/v 0.5 M CaCl 2 with the groups: 'PPP only', 'PRP only', 'PPP + SynthoPlate', 'PRP + SynthoPlate', 'PPP + tissue factor', 'PRP + tissue factor', 'PRP + SynthoPlate + tissue factor', 'PRP + ADP + tissue factor', and 'PRP + ADP + SynthoPlate + tissue factor'. The particle concentration, in the applicable groups, was 5.00 910 10 mL -1 . The resultant thrombin activity was monitored with a Bio-Tek (Winooski, VT, USA) plate reader (excitation/emission at 498/521 nm) for 40 min. Next, for fibrin generation/deposition studies, the PPFC set-up was used as before, with some modifications. Glass slides precoated with 'collagen + VWF' or BSA were sealed within the PPFC, and exposed to flow of fresh 100% PRP (platelet count of 250 000 lL and SynthoPlate (or control) particles, in the presence of fluorescent Fg (Alexa Fluor-647-Fg at 1.5 mg mL À1 added at 3% v/v), with or without ADP. The 'control' particles had only proadhesive peptides (VBP and CBP only; no FMP) such that they can still bind to the 'VWF + collagen' substrate but cannot recruit and aggregate active platelets. The flow was maintained at 50 dyn cm À2 for 15 min. In this set-up, SynthoPlatemediated recruitment and aggregation of active platelets on the 'VWF + collagen' surface was hypothesized to augment the availability of procoagulant active platelet membrane for facilitating secondary hemostatic mechanisms, leading to amplified generation and deposition of fibrin(ogen) during the 15-min time-window (the experiment schematic is show in Fig. S4 ). This deposition was imaged with inverted fluorescence microscopy (emission, 665 nm). At 15 min, the flow was stopped, and the clots on the slides were incubated with streptokinase in PPP (20 lL per mL of PPP) for 60 min. The resultant lysed clots were analyzed with a fibrin D-dimer-specific spectrophotometric ELISA assay (Thermo Fisher) according to the manufacturer's instructions, and D-dimer levels were calculated from a standard calibration curve. The D-dimer analysis was to confirm that the clot fluorescence observed was indeed from fibrin generation and not just Fg.
Effects of SynthoPlate in severely TCP mice
We adapted a model of passive immune thrombocytopenia in mice with platelet-specific antibodies [28] . Wild-type C57/BL6 mice were injected intraperitoneally with a combination of anti-CD41 and anti-CD42 antibodies (1 : 1 ratio at 1-10 lg total) and, 24 h later, platelet counts were performed with an Advia 120 Hematology analyzer (Erlangen, Germany) (six mice per group). For bleeding time assessment, 24 h after administration of 10 lg of antibody, tails of TCP mice were transected 2 mm from the tip with a surgical blade, and immersed in 37°C saline; the time needed for bleeding to stop was recorded (a schematic is shown in Fig. 4A ) [29] . Next, similarly treated TCP mice were injected with 150 lL of various doses (100, 500 or 1000 nL
À1
) of SynthoPlate or control (unmodified) particles via the jugular vein and, 2 h after particle injection, the mouse tails were transected as before to record the bleeding time. The 2-h-circulation time-period was chosen as a feasibility metric for evaluating the 'prophylactic window' of the SynthoPlate technology, and future studies will focus on expanding this window to longer circulation lifetimes. All tail-bleeding studies were performed in accordance with standardization parameters highlighted by the ISTH [30] . After bleeding time studies, mice were killed, and 4-5-mm tail-pieces proximal to the transection site were cut, washed in PBS, fixed in paraformaldehyde for 24 h, and then cryoprotected in 30-60% sucrose and flash frozen in OCT compound (Tissue Tek, Torrance, CA, USA). Cryoblocks were prepared in cryo-molds (Electron Microscopy Sciences, Hatfield, PA, USA) over dry ice and 2-methylbutane, and 9-lm-thick sections were cut with a Leica CM1950 cryostat (Buffalo Grove, IL, USA) and collected on superfrost glass slides (Thermo Fisher) for staining. For immunostaining, frozen sections were air-dried, rinsed in PBS, and blocked with 0.1% Tween-20 and 1% BSA. A sequential staining protocol was followed, in which sections were first incubated with rat anti-mouse CD41 antibodies overnight at 4°C, and then washed in PBS and incubated with an FITC-labeled donkey-anti-rat IgG for 2 h. After additional washes, sections were incubated with rat anti-mouse CD31 for 2 h, and then washed and labeled with goat anti-rat Alexa Fluor-633-IgG. Slides were mounted with Vectashield, and imaged under a Leica fluorescence microscope.
In additional experiments, similar tail sections from TCP mice treated with SynthoPlate or control particles were collected directly into lysis buffer containing protease inhibitors, phosphatase inhibitors, corn trypsin inhibitor, and aprotinin. Tails were disrupted by sonication, and lysates were clarified by centrifugation at 12 000 9 g for 15 min at 4°C. The supernatant was collected, and protein was measured with the Protein DC assay. For immunoblotting, tail extracts were mixed with 5 9 SDS sample buffer containing b-mercaptoethanol, and heated at 95°C for 5 min. Samples were resolved by 10% SDS-PAGE with 25 lg of protein in each lane, and transferred to poly(vinylidene difluoride) membranes. Membranes were probed overnight at 4°C with a 1 : 5000 dilution of rabbit polyclonal Fg/fibrin antibody (Life Span Biosciences). Bound antibody was detected with an HRP-conjugated secondary antibody and super signal west Pico chemiluminescent substrate. The membrane was stripped in stripping buffer containing 15 g L À1 glycine, 1 g L À1 SDS, and 10 mL L À1 Tween-20 (pH 2.2), blocked, and reprobed with antibodies against b-actin.
Assessing the systemic safety and biodistribution of SynthoPlate during 2 h of circulation
For systemic safety analysis, wild-type or TCP mice were intravenously injected with SynthoPlate or control (unmodified) particles and, 2 h after particle injection, blood was collected via cardiac puncture in sodium citrate (0.109 M, 3.2%) and analyzed with an immunoturbidimetric agglutination assay for circulating fibrin D-dimer levels (STA-Liatest D-Di; Diagnostica Stago, Parsippany, NJ, USA), according to the manufacturer's instructions [31] . In parallel experiments, mice were injected intravenously with 8 lg kg À1 lipopolysaccharide (LPS) (positive control) or 120 lL of SynthoPlate or control particles (1000 nL À1 ). At 30 min and 2 h after injection, blood was drawn from the facial vein directly into tubes containing sodium citrate, corn trypsin inhibitor, and aprotinin, and centrifuged at room temperature for 10 min at 850 9 g; the plasma was then collected and analyzed with a double-antibody sandwich ELISA for prothrombin fragment 1 + 2, according to the manufacturer's instructions (Biosource, San Diego, CA, USA). For biodistribution studies, mice were injected intravenously with SynthoPlate, and killed after 2 h with overdose of anesthesia cocktail. Various organs were harvested, rinsed in PBS, and freeze-dried to obtain the dry weight. The organs were homogenized at 4000 r.p.m. (BeadBug Microtube Homogenizer; Benchmark Scientific, Edison, NJ, USA), and homogenates were shaken overnight at 750 r.p.m. and 37°C with 1 : 1 methanol/chloroform solution to extract the RhB-labeled lipids. The resultant samples were centrifuged at 1000 9 g for 10 min, the supernatant containing RhB-labeled lipids was collected, and the fluorescence in the supernatant was determined with a Bio-Tek Plate reader (excitation, 550 nm; emission, 590 nm). The SynthoPlate percentage in various organs was determined by calculating the concentration (ng mL
) of particles in the supernatant from a calibration curve. In complementary studies, SynthoPlate particles were radiolabeled either by incorporating 3 H-tagged cholesteryl ester in the vesicle membrane, or encapsulating indium chloride ( 111 InCl 3 ) in the vesicle core (representative results are shown in Fig. S5 ). Following tail-vein injection of these particles, mice were either killed for harvesting of organs and blood for scintillation counting of 3 H-labeled particles, or wholebody imaged by single photon emission computed tomography for assessment of the 111 InCl 3 -labeled particle distribution.
Statistical analysis
Where applicable, data were expressed as mean AE standard deviation. Aggregometry results were analyzed by one-way ANOVA with Bonferroni post hoc testing for multiple comparisons by the use of SIGMASTAT 3.5. Thrombin and fibrin assay results were analyzed by one-way ANOVA and Tukey's test. For some in vivo results, analyses were also carried out with a two-tailed Student's t-test. A P-value of < 0.05 was considered to be statistically significant.
Results
In vitro studies of SynthoPlate-mediated primary hemostasis mechanisms
Representative aggregometry data for PRP or washed platelets, along with corresponding histograms of percentage aggregation, are shown in Fig. 2 . As is evident from Fig. 2A1 , without platelet activation, SynthoPlate itself has no aggregatory effect on platelets, as the turbidimetric trace for this (brown) was same as that for resting (without ADP) platelets (indigo). This suggests that SynthoPlate will not activate resting platelets in the circulation. Upon agonist addition, platelet aggregation was observed in 100% PRP as well as in 100% platelets (green traces in Fig. 2A1,  B1 ). This aggregation was significantly reduced when PRP was diluted by 50% v/v with PPP or platelets were diluted with saline (purple traces in Fig. 2A1,B1 ). This dilution effect was not rescued when control (unmodified) particles were added (red traces in Fig. 2A1,B1 ). In contrast, addition of SynthoPlate particles significantly rescued the aggregation (cyan traces in Fig. 2A1,2B1 ). Statistical analyses (Fig. 2A2,B2 ) clearly show this ability of SynthoPlate to improve the aggregation of diluted platelets. Also, the SynthoPlate vesicles themselves did not show any aggregation in presence of platelet agonists and Ca 2+ (Fig. S6) . Fluorescence microscopy studies in PPFC demonstrated that RhB-labeled (red fluorescent) SynthoPlate particles showed significant colocalization (yellow overlay) with calcein-stained (green fluorescent) active platelets on a 'VWF + collagen' surface, whereas unmodified, 'adhesion-only' and 'aggregation-only' particles showed minimal colocalization (Fig. S3B) . These results are in accordance with our previously reported findings [19, 20] . Altogether, these studies indicate that: (i) SynthoPlate interacts specifically with activated platelets to augment their aggregation; and (ii) this aggregation can be enhanced selectively at the site of 'VWF + collagen' exposure (amplification of primary hemostasis) via SynthoPlate action. In vitro studies of SynthoPlate-mediated thrombin generation Figure 3A shows the table for thrombin generation parameters obtained for the various groups studied. As is evident from the results, without tissue factor or platelet agonist (ADP), addition of SynthoPlate to recalcified PRP or PPP did not induce or accelerate rapid thrombin generation, and thrombin generation occurred with a much longer lag time, as is common for recalcified plasma [32] . In the presence of tissue factor and/or ADP, thrombin generation was drastically accelerated in PRP (or PPP) even without SynthoPlate, and the reaction speed increased slightly when SynthoPlate was present. This indicates that SynthoPlate itself does not directly influence thrombin generation in plasma, but can possibly indirectly influence thrombin generation if it can recruit procoagulant active platelets at the site of injury and tissue factor exposure. This possibility was further confirmed by the results of the fibrin(ogen) generation/deposition study under flow (representative images and quantitative results are shown in Fig. 3B,C) . In this case, during the 15-min time-window, the fluorescence of deposited fibrin(ogen) significantly increased when ADP-activated 50% PRP was passed with SynthoPlate over a 'VWF + collagen' surface, as compared with the control conditions. The D-dimer ELISA studies further confirmed that the deposited clot in this group contained a significant amount of fibrin (Fig. 3D ). All together, these studies confirm that SynthoPlate does not have any innate ability to stimulate coagulation in plasma (and therefore has a minimum systemic procoagulant risk), but can, 'in effect', augment coagulatory output at the injury site by enhancing the recruitment and aggregation of active platelets at the site.
Severe thrombocytopenia induction in mice and effects of SynthoPlate on tail bleeding Figure 4A1 shows the platelet count following antibody treatment, demonstrating that a total dose of 10 lg of antibody combination (5 lg each) resulted in a~90% reduction in platelet count (severe thrombocytopenia). Injection of PBS or non-specific mouse IgG (MOPC-21) did not deplete platelets. The effect of platelet depletion on the hemostatic capacity of mice is shown in Fig. 4A2 , where 10 lg of antibody injection (i.e. platelet depletion by~90%) resulted in a four-fold to five-fold increase in tail-bleeding time. This severe thrombocytopenia condition was subsequently used to test the ability of prophylactically administered SynthoPlate to improve hemostasis. Figure 4B shows the effect of SynthoPlate versus control particle treatment on tail-bleeding time in TCP mice. As is evident, PBS alone or control particles were unable to correct the prolonged bleeding time (400-500 s). In contrast, SynthoPlate was able to significantly correct the bleeding time in a dose-dependent manner.
The highest dose of SynthoPlate (1000 nL
À1
, equivalent to the murine native platelet concentration) reduced the bleeding time to~150 s (> 60% reduction as compared with controls), which is close to that of normal mice (~100 s, shown for comparison). These studies demonstrate that SynthoPlate could efficiently correct the hemostatic defect in thrombocytopenia. Figure 5A ,B shows representative immunofluorescence images of cryosectioned tail tissue immediately proximal to the tail transection site, showing vascular endothelium (CD31 in blue), particle fluorescence (red), platelets (CD41 in green), and corresponding overlays, for SynthoPlate-treated versus control particle-treated TCP mice. Figure 5C shows the percentage of the vasculature that demonstrated colocalization of CD41 (platelets) and SynthoPlate (or control) particles, determined from 24 representative images per injection group (six mice per group) by manual counting. These images clearly indicate that SynthoPlate has significantly greater ability than control (unmodified) particles to enhance the recruitment and aggregation of platelets in the injured vessels in TCP mice. Figure 5D shows representative immunoblot data (for fibrin/Fg, and for b-actin as a loading control) for tail tissue from SynthoPlate-treated versus control particle-treated TCP mice. Individual Fg a, b and c chains are not well resolved, but are seen as prominent bands of~45-63 kDa. However, higher molecular weight bands, consistent with thrombin-cleaved cross-linked fibrin, are apparent in the SynthoPlate-treated mice (lanes 3 and 4) , but are not present in control particle-treated mice (lanes 1 and 2) . These results further indicate that, in TCP mice, SynthoPlate-mediated platelet recruitment and aggregation at the injury site (amplification of primary hemostasis) also enhance thrombin generation and fibrin deposition at the site (secondary hemostasis) to improve overall hemostatic capability.
Systemic safety and biodistribution of SynthoPlate during 2 h of circulation Figure 6A shows 30-min and 2-h time-point results for ELISA-based analysis of prothrombin fragment 1 + 2 in SynthoPlate-injected mice (untreated mice or LPS-injected mice as controls). SynthoPlate particles did not enhance prothrombin fragment levels, indicating their minimum procoagulant activity in plasma. This was further validated by the Stago D-dimer assay results shown in Fig. 6B , where neither control nor TCP mice were found to have enhanced levels of fibrin D-dimer in the systemic circulation at the 2-h time-point following SynthoPlate or control particle administration (as compared with manufacturer-supplied controls). These in vivo results, combined with those of previous in vitro assays, further establish that SynthoPlate does not have systemic prothrombotic and procoagulant effects. hemostasis in the event of injury. In fact, complementary studies using radiolabeled particles (representative data are shown in Fig. S5 ) further indicate that SynthoPlate has a reasonably long circulation residence time. As SynthoPlate design utilizes polyethylene glycol-decorated lipid vesicles, this long circulation capability and low clearance are in good agreement with reports for similar nanoparticles (e.g. Stealth liposomes) [23] .
Discussion
Synthetic platelet substitutes can potentially resolve many issues that currently complicate platelet transfusion [13, 14, 33, 34] . Several previous 'synthetic platelet' designs have focused on amplifying the 'platelet aggregation' mechanism by coating synthetic particles with Fg or Fgrelevant peptides, but have not yet been translated into clinical application [35] [36] [37] . We rationalized that promoting platelet aggregation without a synergistic mechanism of bleeding site-selective adhesion may result in systemic prothrombotic risks from free-floating aggregates. Therefore, we have developed a synthetic platelet technology (SynthoPlate) that combines platelet-mimetic adhesion and aggregation functionalities on a biocompatible lipid vesicle, and have previously demonstrated the advantage of this integrative design in vitro and in vivo in normal mice [19, 20] . Building on these findings, in our current studies we established that the SynthoPlate vesicles themselves do not have systemic prothrombotic or procoagulant risks, but can amplify activated platelet-mediated primary and secondary hemostatic mechanisms selectively at a bleeding site, even at low platelet concentrations. Our in vivo studies further confirmed that prophylactic administration of SynthoPlate can dose-dependently improve hemostasis in a tail-bleeding model in severely TCP mice, with higher doses being capable of correcting bleeding times to levels comparable to that of normal mice. One should note that the starting platelet count in normal mice (~1 million per microliter) is significantly higher than that in normal human (~250 000 per microliter), and hence the severity of the TCP bleeding risk in mice is associated with the percentage platelet depletion and not the absolute number of remaining platelets. Also, as tail-bleeding studies may have some experimental heterogeneity, we have meticulously followed the ISTH standardization recommendations for this model to minimize errors and variabilities [30] . Immunofluorescence microscopy and immunoblot analyses confirmed striking colocalization of murine platelets and SynthoPlate, as well as enhanced formation of fibrin in hemostatic foci of SynthoPlate-injected mice. In vivo, SynthoPlate vesicles showed reasonably long circulation periods, and were primarily cleared by the liver and spleen. The SynthoPlate technology may also find potential uses in the emergency treatment of traumatic hemorrhage, and as a targeted drug delivery platform in various platelet-relevant diseases [38] [39] [40] . Data S1. Ligand density calculation on SynthoPlate vesicle surface. Fig. S1 . Cartoon representation of the design and envisioned mechanism components of SynthoPlate. Fig. S2 . Representative MALDI-TOF mass spectrometry characterization data for the peptides VBP, CBP and FMP, the DSPE-PEG lipid molecule to which these peptides were conjugated, and the resultant DSPE-PEG-peptide conjugates for the three peptides. Fig. S3 . Experimental set-up for parallel-plate flow chamber studies where RhB-labeled (red fluorescent) SynthoPlate (SP), 'adhesion only', 'aggregation only' or 'unmodified' particles were flowed with calcein-stained (green fluorescent) active platelets (aPLT) over 'VWF + collagen'-coated surfaces. Fig. S4 . Experimental design schematic for assessing fibrin(ogen) generation/deposition on 'VWF + collagen'-coated surface when platelets (with or without ADP) are flowed in re-calcified plasma containing fluorescent fibrinogen along with SynthoPlate. Fig. S5 . Scintillation counting based biodistribution data for radiolabeled SynthoPlate vesicles in mouse (left) and representative SPECT-CT image data in mouse for PEGylated SynthoPlate distribution compared with that for free radiolabel as well as non-PEGylated radiolabeled vesicles. Fig. S6 . Representative turbidimetric aggregometry study results of just SynthoPlate TM or just control particles in buffer, without platelets but with agonists (ADP or collagen) show that the vesicles themselves do not have any major aggregation capacity.
